Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Samsung Bioepis Celebrates Soliris Success

Phase I Results For SB12 Eculizumab Biosimilar Candidate Demonstrate Equivalence

17 Dec 2021

• By Dave Wallace

clinical trials — Samsung Bioepis has announced Phase I trial results for its eculizumab • Source: Shutterstock

Related Content

Samsung Bioepis Moves Forward With Soliris Rival

01 Nov 2021

How Samsung Bioepis Is Laying A Path For Ophthalmic Biosimilars

10 Dec 2021

Amgen Chooses To Settle In US Soliris IPR Tussle

03 Jun 2020

Alexion To Join With AZ Ahead Of US Soliris Biosimilars In 2025

14 Dec 2020

Related Companies

Samsung Bioepis Co., Ltd.

Additional Topics

Biosimilars Clinical Trials Strategy BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.